U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H32N2O9
Molecular Weight 528.551
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAMSIRUBICIN

SMILES

[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@](O)(CCO)CC3=C(O)C4=C(C(=N)C5=C(OC)C=CC=C5C4=O)C(O)=C23

InChI

InChIKey=GNCWGPLZJLZZPI-KUIJCEFOSA-N
InChI=1S/C27H32N2O9/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3/t11-,14-,16-,17-,23+,27-/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H32N2O9
Molecular Weight 528.551
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

GPX-150 is an anthracycline compound that is being tested for treatment in patients with soft-tissue sarcomas. This doxorubicin (DOX) analog does not show the cumulative dose-dependent cardiotoxicity of DOX. It works by reducing the formation of reactive oxygen species and the cardiotoxic metabolite, doxorubiciniol, the two pathways that are linked to the irreversible cardiotoxicity seen with DOX. Phase 1 clinical trials showed no irreversible, cumulative dose-dependent cardiotoxicity. A phase 2 study investigating the safety and efficacy of GPX-150 in patients with soft tissue sarcoma has been completed. No patients developed any evidence of irreversible, cumulative dose-dependent chronic cardiotoxicity. Toxicities reported include grade 3 anemia, neutropenia, and grade 4 leukopenia.

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 03:21:16 UTC 2023
Edited
by admin
on Sat Dec 16 03:21:16 UTC 2023
Record UNII
VI79RD8VNN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAMSIRUBICIN
INN  
Official Name English
5-IMINO-13-DEOXYDOXORUBICIN
Common Name English
Camsirubicin [WHO-DD]
Common Name English
GPX-150
Common Name English
5(8H)-NAPHTHACENONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,9,10,12-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(2-HYDROXYETHYL)-12-IMINO-1-METHOXY-, (8R,10S)-
Systematic Name English
camsirubicin [INN]
Common Name English
(8R,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,9,10,12-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(2-HYDROXYETHYL)-12-IMINO-1-METHOXY-5(8H)-NAPHTHACENONE
Systematic Name English
(8R,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXOHEXOPYRANOSYL) OXY)-6,8,11-TRIHYDROXY-8-(2-HYDROXYETHYL)- 12-IMINO-1-METHOXY-7,9,10,12-TETRAHYDROTETRACEN-5(8H)- ONE
Systematic Name English
GPX150
Code English
Classification Tree Code System Code
NCI_THESAURUS C1594
Created by admin on Sat Dec 16 03:21:16 UTC 2023 , Edited by admin on Sat Dec 16 03:21:16 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C78863
Created by admin on Sat Dec 16 03:21:16 UTC 2023 , Edited by admin on Sat Dec 16 03:21:16 UTC 2023
PRIMARY
PUBCHEM
135446069
Created by admin on Sat Dec 16 03:21:16 UTC 2023 , Edited by admin on Sat Dec 16 03:21:16 UTC 2023
PRIMARY
SMS_ID
100000183564
Created by admin on Sat Dec 16 03:21:16 UTC 2023 , Edited by admin on Sat Dec 16 03:21:16 UTC 2023
PRIMARY
CAS
236095-26-4
Created by admin on Sat Dec 16 03:21:16 UTC 2023 , Edited by admin on Sat Dec 16 03:21:16 UTC 2023
PRIMARY
DRUG BANK
DB13103
Created by admin on Sat Dec 16 03:21:16 UTC 2023 , Edited by admin on Sat Dec 16 03:21:16 UTC 2023
PRIMARY
INN
10847
Created by admin on Sat Dec 16 03:21:16 UTC 2023 , Edited by admin on Sat Dec 16 03:21:16 UTC 2023
PRIMARY
FDA UNII
VI79RD8VNN
Created by admin on Sat Dec 16 03:21:16 UTC 2023 , Edited by admin on Sat Dec 16 03:21:16 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY